UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/580,556	05/26/2006	Sang Yup Lee	4240-142	1480
23448 7590 04/09/2008 INTELLECTUAL PROPERTY / TECHNOLOGY LAW PO BOX 14329 PESEA DOM: TRIANCLE DADI/, NO. 27700			EXAMINER	
			MEAH, MOHAMMAD Y	
RESEARCH TRIANGLE PARK, NC 27709		27709	ART UNIT	PAPER NUMBER
			1652	
			MAIL DATE	DELIVERY MODE
			04/09/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/580,556	LEE ET AL.			
Office Action Summary	Examiner	Art Unit			
	MD. YOUNUS MEAH	1652			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
1) ☐ Responsive to communication(s) filed on 23 Ja 2a) ☐ This action is FINAL . 2b) ☐ This 3) ☐ Since this application is in condition for allowant closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro				
Disposition of Claims					
4) Claim(s) 1-30 and 32-35 is/are pending in the a 4a) Of the above claim(s) 1,3-7,10-30 and 33-3 5) Claim(s) 8 and 9 is/are allowed. 6) Claim(s) 2 and 32 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or	<u>5</u> is/are withdrawn from consider	ation.			
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the of Replacement drawing sheet(s) including the correction in the original sheet (s). 11) The oath or declaration is objected to by the Examiner.	epted or b) objected to by the Edrawing(s) be held in abeyance. See on is required if the drawing(s) is obj	e 37 CFR 1.85(a). lected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 2/20/08.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	nte			

DETAILED ACTION

Claims 1-31, 33-35 are pending. Claims 2, 8-9, 31-32 were examined in the previous action. Claims 1, 3-7, 10-30 and 33-35 remain withdrawn. On 1/23/08, applicant canceled claim 31 and amended claims 2, and 32. Claims 2, 8-9 and 32 will be examined.

Abstract

The abstract of the disclosure is objected to because not submitting in a separate page. Correction is required. See MPEP § 608.01(b).

35 U.S.C 112 Rejection

35 U.S.C 112 2nd paragraph

The 112 2nd paragraph rejections of claims 2 and 32 became moot because of the amendment of the claims.

35 U.S.C 112 1st paragraph Rejection

Rejection of Claims 8-9 under 35 U.S.C. 112, first paragraph is withdrawn after finding applicants' argument and statement persuasive.

Art Unit: 1652

Rejection of Claims 2 and 32 under 35 U.S.C. 112, first paragraph Written Description requirement is withdrawn after amendment of the claims and applicant arguments found to be persuasive.

Rejection of Claims 2 and 32 under 35 U.S.C. 112, first paragraph Enablement requirement is withdrawn after amendment of the claims and finding applicant arguments to be persuasive.

CLAIM Rejection - 35 U.S.C 103a

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 2 and 32 are rejected under 35 U.S.C. 103(a) by Vemuri et al.(Appld and envrn Microbiol 2002, pp 1715-1727, From IDS) in view of Chang et al. (Appld and envrn Microbiol 1999, pp 1384-1389).

Claims 2 and 32 are drawn to a rumen bacteria selected from *Mannheimia*, *Actinobacillu or anaerobiospirillum* wherein genes of *ackA*, *IdhA*, *pfl* and *pta*, enzymes in metabolic carboxylic acid pathway are disrupted in order to enhance the production of succinic acid without producing any other organic acid.

Vemuri et al teaches that lack of *IdhA*, *pfl* in *E. coli* strain NZN111 and *IdhA*, *pfl* and *pta* in *E. coli* strain AFP 111 increase the production of succinic acid as metabolic pathway for production of ethanol, lactate is disrupted. However Vemuri et al does not teach disruption of *ackA* gene and more over said strain shows production of acetate.

Mannheimia, Actinobacillu or anaerobiospirillum (applicants' amendment page 11) and E. coli (Chang et al. (Appld and envrn Microbiol 1999, pp 1384-1389) have identical fermentation pathway for carboxylic acid metabolism. One knowledgeable in prior art knows that disrupting one or other enzyme of a metabolic pathway would disrupt the production of product results from said enzyme (such as disrupting ldhA decrease lactic acid production and by doing it enhance production other product such as succinic acid, etc). Chang et al. teach that disrupting ackA gene in E.coli in addition of disruption of pta to increase the production of lactate as metabolic pathway for the production of acetate is disrupted. In other word it is well known in art that disruption of particular pathway enzyme decrease that production of that metabolite. Such as disruption of ackA disrupt acetate formation. Disrupting IdhA disrupt lactate formation, etc. Therefore, there is a motivation to disrupt ackA gene in addition of IdhA, pfl and pta genes in the fermentation pathway for carboxylic acid metabolism of microorganism to disrupt the production of acetate in order further increase the production of succinic acid.

As such it would have been obvious to one of ordinary skill in the art to disrupt ackA gene (as taught by Chang et al.) in addition to IdhA, pfl and pta gene in fermentation pathway for carboxylic acid metabolism (as taught by Vemuri et al, since Art Unit: 1652

rumen bacteria's fermantive pathway are identical to that of *E. coli*) in rumen organism comprising *Mannheimia*, *Actinobacillu or anaerobiospirillum* as more than likely said mutant bacteria produce more succinic acid without production of other metabolic pathway products including acetate.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mohammad Meah whose telephone number is 571-272-1261. The examiner can normally be reached on 8:30-5PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Mohammad Meah/
Acting Examiner of Art Unit 1652/1600
Mohammad Younus Meah, PhD
Examiner, Art Unit 1652
Recombinant Enzymes, 3C31 Remsen Bld
400 Dulany Street, Alexandria, VA 22314

Telephone: 517-272-1261

Application/Control Number: 10/580,556 Page 6

Art Unit: 1652